Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003197 · ClinicalTrials.gov registry record · Phase 1
Green Tea Extract in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00003197: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003197 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003197, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers, as well as prevent the development of new cancers. PURPOSE: Phase I trial to study the effectiveness of green tea extract in treating patients with advanced solid tumors that are refractory to standard therapy.
Interventions
- DIETARY_SUPPLEMENT green tea extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-12 |
| Est. Completion | 2000-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003197
The ClinicalTrials.gov registry entry for NCT00003197 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which green tea extract is the first listed.
NCT00003197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003197 about?
NCT00003197 is a clinical study titled "Green Tea Extract in Treating Patients With Advanced Solid Tumors". RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers, as well as prevent the development of new cancers. PURPOSE: Phase I trial to study the effectiveness of green tea extract in treating patients with advanced solid tumors that are refractory to standard th...
What is the current status of trial NCT00003197?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1997-12. Estimated completion is 2000-06.
What interventions are being tested in trial NCT00003197?
The interventions under investigation include: green tea extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00003197?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.